5-year Relative Survival
The 5-year relative survival for MZL is reported by the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database (n=9805).1
5-year relative survival (%)1
NHL subtype, disease stage, and disease grade are all associated with each patient’s prognosis.2 Indices have been created that combine the relative input of disease stage and other prognostic factors—including age, ECOG performance status, and serum LDH—into a single score that helps determine prognosis.2 Prognostic indices vary between lymphoma subtypes; separate indices have been developed for aggressive NHL (like DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL), but not marginal zone lymphoma (MZL).2 However, the Follicular Lymphoma International Prognostic Index, or FLIPI score has been demonstrated to have strong prognostic value in patients with extranodal or splenic MZL.3
MZL may transform into aggressive NHL, most often DLBCL. The risk of histologic transformation is low, but is associated with a worse clinical outcome.4-6 Pathologic evaluation for histologic transformation should include FISH for BCL6 and MYC rearrangements.2
DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; FLIPI, Follicular Lymphoma International Prognosis Index.